Related Experiment Videos

Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis

Cristina Meazza1, Paola Travaglino, Patrizia Pignatti

  • 1University of Pavia, IRCCS Policlinico San Matteo, Italy.

Arthritis and Rheumatism
|January 31, 2002
PubMed
Abstract

Insights

Macrophage migration inhibitory factor (MIF) is elevated in juvenile idiopathic arthritis (JIA), especially systemic-onset JIA. Higher MIF levels correlate with disease activity and reduced remission duration, suggesting its role in JIA pathogenesis.

Area of Science:

  • Immunology
  • Rheumatology
  • Cytokine Research

Background:

  • Juvenile idiopathic arthritis (JIA) is a complex autoimmune disease.
  • Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine with a potential role in autoimmune conditions.

Purpose of the Study:

  • To investigate serum and synovial fluid (SF) levels of MIF in JIA patients.
  • To assess in vitro MIF production by peripheral blood mononuclear cells (PBMCs) in JIA.
  • To explore the correlation of MIF levels with clinical parameters of JIA.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to quantify MIF levels in serum and SF.
  • PBMCs were cultured with and without concanavalin A to measure MIF production.
  • Correlations between MIF levels and clinical features of JIA were analyzed.

Main Results:

  • Serum MIF levels were significantly higher in JIA patients, particularly those with systemic-onset JIA.
  • PBMCs from systemic-onset JIA patients produced more MIF in vitro.
  • SF MIF levels were higher in systemic-onset JIA than oligoarticular-onset JIA and inversely correlated with remission duration after intraarticular corticosteroid treatment.

Conclusions:

  • MIF is implicated in the pathogenesis of JIA, especially the systemic subtype.
  • MIF may serve as a biomarker for disease activity and treatment response in JIA.

Related Concept Videos